相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Alzheimer's Association Report 2011 Alzheimer's disease facts and figures
ALZHEIMERS & DEMENTIA (2011)
Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease
Tanya L. Wallace et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography
Kai Kendziorra et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Pharmacokinetics, Safety, and Tolerability Following Multiple Oral Doses of Varenicline Under Various Titration Schedules in Elderly Nonsmokers
Qinying Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment
Geoffrey C. Dunbar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia
Mu-En Liu et al.
PSYCHIATRY RESEARCH (2011)
Pre-clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence
H. Rollema et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation
Helene M. Faessel et al.
CLINICAL PHARMACOKINETICS (2010)
Quantitative Assessment of Exposure-Response Relationships for the Efficacy and Tolerability of Varenicline for Smoking Cessation
P. Ravva et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease
G. Maher-Edwards et al.
CURRENT ALZHEIMER RESEARCH (2010)
Preclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects on reward, mood and cognition
Hans Rollema et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Varenicline Improves Mood and Cognition During Smoking Abstinence
Freda Patterson et al.
BIOLOGICAL PSYCHIATRY (2009)
Population pharmacokinetic analysis of varenicline in adult smokers
Patanjali Ravva et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Association between a Genetic Variant of the Alpha-7 Nicotinic Acetylcholine Receptor Subunit and Four Types of Dementia
Agnes Feher et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2009)
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder
Robert C. Smith et al.
SCHIZOPHRENIA RESEARCH (2009)
Behavioral effects of current Alzheimer's disease treatments: A descriptive review
Jeffrey L. Cummings et al.
ALZHEIMERS & DEMENTIA (2008)
Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI) (vol 21, pg 171, 2007)
Geoffrey C. Dunbar
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Neuronal nicotinic receptors: A perspective on two decades of drug discovery research
Stephen P. Arneric et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers
G. Dunbar et al.
PSYCHOPHARMACOLOGY (2007)
Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
H. Rollema et al.
NEUROPHARMACOLOGY (2007)
Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)
Geoffrey C. Dunbar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2007)
Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers
Helene M. Faessel et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers
Aaron H. Burstein et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation -: A randomized controlled trial
David Gonzales et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation -: A randomized controlled trial
Douglas E. Jorenby et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam
P Maruff et al.
PSYCHOPHARMACOLOGY (2006)
Varenicline:: An α4β2 nicotinic receptor partial agonist for smoking cessation
JW Coe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer's disease patients
LW Chu et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2005)
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
C Holmes et al.
NEUROLOGY (2004)
Association analysis of the partially duplicated α7 nicotinic acetylcholine receptor genetic variant and Alzheimer's disease
YJ Liou et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2001)
Neuronal nicotinic receptors in the human brain
D Paterson et al.
PROGRESS IN NEUROBIOLOGY (2000)
Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease
A Maelicke
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2000)
分享论文
